N/A
N=224
To Evaluate Effectiveness and Safety of GP0109 for Jawline Definition
Jawline Definition Deficiency
Bottom Line
View on ClinicalTrials.gov: NCT05110287 ↗Enrolled (actual)
224
Serious AEs
2.7%
Results posted
May 2026
Primary outcome: Primary: Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) — 14.3; 85.1 percentage of participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- GP0109 (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Galderma R&D
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Responders Based on Blinded Evaluators' Live Assessment of the Galderma Jawline Scale (GJS) |
14.3; 85.1 | <0.001 sig |
Summary
This study is designed to evaluate effectiveness and safety of GP0109 for Jawline definition
Eligibility Criteria
Inclusion Criteria
- Males or non-pregnant, non-breastfeeding females, over the age of 21.
Exclusion Criteria
- Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins
- Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.
Data sourced from ClinicalTrials.gov (NCT05110287). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.